Compare GATX & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GATX | BLLN |
|---|---|---|
| Founded | 1898 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Transportation Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.0B |
| IPO Year | 1994 | N/A |
| Metric | GATX | BLLN |
|---|---|---|
| Price | $178.96 | $132.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $215.50 | $126.71 |
| AVG Volume (30 Days) | 210.6K | ★ 706.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ 17.22 | N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $1,740,400,000.00 | N/A |
| Revenue This Year | $42.21 | $46.29 |
| Revenue Next Year | $3.35 | $30.14 |
| P/E Ratio | $75.80 | ★ N/A |
| Revenue Growth | ★ 9.77 | N/A |
| 52 Week Low | $148.20 | $61.96 |
| 52 Week High | $205.56 | $138.70 |
| Indicator | GATX | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 64.49 |
| Support Level | $166.38 | $79.07 |
| Resistance Level | $183.47 | $138.70 |
| Average True Range (ATR) | 4.86 | 7.07 |
| MACD | 0.24 | -0.17 |
| Stochastic Oscillator | 73.90 | 92.55 |
GATX Corp leases transportation assets, including railcars, aircraft spare engines, and tank containers, to customers in North America, Europe, and India. The company's reportable business segments are: Rail North America, Rail International, Engine Leasing, and Other. The majority of its revenue is generated from the Rail North America segment, which is composed of the company's operations in the United States, Canada, and Mexico. This segment mainly provides railcars pursuant to full-service leases under which it maintains the railcars, pays ad valorem taxes and insurance, and provides other ancillary services.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.